Breaking News Instant updates and real-time market news.

ALNY

Alnylam

$78.12

0.37 (0.48%)

, BMRN

BioMarin

$86.67

-0.31 (-0.36%)

10:55
07/19/17
07/19
10:55
07/19/17
10:55

JPMorgan European pharma/biotech analysts hold analyst/industry conference call

U.S. SMid Biotech Analysts along with Key Opinion Leader Dr. Guy Young, MD., from the University of Southern California discuss multiple hemophilia program updates from the recently held International Society on Thrombosis and Haemostasis (ISTH) 2017 Congress on an Analyst/Industry conference call to be held on July 19 at 11:30 am.

ALNY

Alnylam

$78.12

0.37 (0.48%)

BMRN

BioMarin

$86.67

-0.31 (-0.36%)

ONCE

Spark Therapeutics

$61.52

0.87 (1.43%)

SHPG

Shire

$164.37

0.63 (0.38%)

RHHBY

Roche

$31.85

-0.09 (-0.28%)

  • 19

    Jul

  • 30

    Jul

  • 02

    Aug

  • 11

    Sep

  • 12

    Jan

ALNY Alnylam
$78.12

0.37 (0.48%)

07/11/17
FBCO
07/11/17
NO CHANGE
Target $96
FBCO
Outperform
Alnylam weakness more driven by competitor data, says Credit Suisse
While attending the ISTH meeting in Berlin, Credit Suisse analyst Alethia Young notes that Alnylam's (ALNY) stock weakness is more driven by "strong" competitor data in inhibitors from Roche's (RHHBY) ACE910. The analyst reiterates an Outperform rating and $96 price target on Alnylam's shares.
07/11/17
BMOC
07/11/17
NO CHANGE
BMOC
Alnylam weakness creates buying opportunity, says BMO Capital
BMO Capital analyst Do Kim says that the weakness of Alnylam's stock was caused by increases in ALT associated with the company's fitusiran drug. But the analyst says that such increases are "transient and asymptomatic," and Kim believes that the drug is superior to competing products. Kim recommends buying the stock on weakness.
07/11/17
COWN
07/11/17
NO CHANGE
Target $325
COWN
Outperform
Shire hemophilia franchise being valued near zero, says Cowen
Cowen analyst Ken Cacciatore believes Shire's (SHPG) current valuation reflects essentially no value for the company's hemophilia franchise. Investors are treating Shire/Baxalta's hemophilia franchise as if it should equate to essentially zero, into perpetuity, beginning in 2020, Cacciatore tells investors in a research note, citing his analysis. He believes this sentiment, based on competitive concerns from Roche (RHHBY) and Alnylam (ALNY), is a "gross overreaction." The analyst has an Outperform rating on Shire with a $325 price target.
07/17/17
LTCO
07/17/17
NO CHANGE
Target $90
LTCO
Buy
Alnylam price target raised to $90 from $80 at Ladenburg
Ladenburg Thalmann analyst Christopher James raised his price target for Alnylam Pharmaceuticals to $90 ahead of the upcoming Phase 3 APOLLO readout with patisiran. The analyst says his new target reflects increased confidence in a positive readout. He upped his probability of success for patisiran to 80% from 70% and keeps a Buy rating on Alnylam.
BMRN BioMarin
$86.67

-0.31 (-0.36%)

04/28/17
DBAB
04/28/17
NO CHANGE
Target $105
DBAB
Buy
Deutsche ups BioMarin target to $105 on Brineura approval
Deutsche Bank analyst Andrew Peters believes the FDA approval of BioMarin's Brineura is another important step in the company's evolution. The addition of another $300M-plus product further underscores BioMarin's long-term growth profile the analyst tells investors in a research note. Peters raised his price target for the shares to $105 from $103 and reiterates a Buy rating on BioMarin.
07/13/17
DBAB
07/13/17
NO CHANGE
Target $118
DBAB
Buy
BioMarin meetings confirm favorable hemophilia outlook, says Deutsche Bank
Deutsche Bank analyst Andrew Peters says BioMarin remains one of his top-picks in the Biotech sector after hosting investor meetings in Europe with management. The analyst views the data for the company's hemophilia program as "quite strong." The data and decision to move forward with the high-dose cohort into Phase 3 trials is very positive and the subsequent stock reaction "does not appreciate the implications" of the hemophilia update, Peters tells investors in a research note. He reiterates a Buy rating on BioMarin with a $118 price target.
07/18/17
PIPR
07/18/17
NO CHANGE
Target $43
PIPR
Overweight
BioMarin pact removes patent uncertainty for Sarepta, says Piper Jaffray
Piper Jaffray analyst Edward Tenthoff said Sarepta's (SRPT) DMD license agreement with BioMarin (BMRN) "effectively ends" global patent litigation between the two and removes patent uncertainty for Sarepta, freeing the company to focus on drug commercialization and development. He keeps an Overweight rating and $43 price target on Sarepta shares.
07/19/17
RHCO
07/19/17
NO CHANGE
RHCO
Sarepta deal 'highly positive,' says SunTrust
After Sarepta (SRPT) and BioMarin (BMRN) announced a license agreement, SunTrust analyst Edward Nash says the deal resolves a patent dispute between the companies and terminates Sarepta's IP overhang. The analyst says that the deal "effectively provided Sarepta with exclusive rights to BioMarin's DMD patent estate," while the single digit royalty payments to BioMarin are also favorable for Sarepta. He calls the deal "highly positive" for Sarepta and keeps a Buy rating on the stock. .
ONCE Spark Therapeutics
$61.52

0.87 (1.43%)

06/28/17
WBLR
06/28/17
INITIATION
WBLR
Outperform
Spark Therapeutics initiated with an Outperform at William Blair
William Blair analyst Raju Prasad started Spark Therapeutics with an Outperform rating saying the company is a leader in gene therapy.
06/29/17
RHCO
06/29/17
NO CHANGE
RHCO
Expert upbeat on Spark Therapeutics hemophilia drug, says SunTrust
After speaking with a hemophilia expert, SunTrust analyst Edward Nash reports that the expert is upbeat on Spark's hemopihlia treatment, SPK-9001. Specifically, the expert says that the drug achieves "high FIX levels using a low dose," Nash reported. The expert adds that he does not believe that the drug's use of Padua raises any safety concerns, noted Nash. The analyst says that " SPK-9001 appears to be the most promising gene therapy program for the treatment of hemophilia B." He keeps a Buy rating on Spark.
07/10/17
JEFF
07/10/17
INITIATION
Target $85
JEFF
Buy
Spark Therapeutics initiated with a Buy at Jefferies
Jefferies analyst Michael Yee initiated Spark Therapeutics with a Buy and an $85 price target.
07/11/17
JEFF
07/11/17
NO CHANGE
JEFF
Jefferies fundamentally positive on Biotechnology, lists top picks
Jefferies analyst Michael Yee rolled out coverage of 12 Biotechnology names in a 550 page research report. The analyst is "fundamentally positive" on the sector, believing investor interest in large-caps will pick up "as the road to repair slowly continues." He believes the smid-cap space is "becoming a good stock-pickers' market." Yee's top picks in Biotech space include Celgene (CELG), Vertex (VRTX), Spark Therapeutics (ONCE), Prothena (PRTA) and Intercept (ICPT). The analyst's best picks in the smid-cap space are Spark, Prothena, Intercept and FibroGen (FGEN).
SHPG Shire
$164.37

0.63 (0.38%)

07/06/17
HSBC
07/06/17
UPGRADE
HSBC
Hold
Shire upgraded to Hold from Reduce at HSBC
HSBC analyst Steve McGarry upgraded Shire to Hold saying any haemophilia-related headline risk should be largely reflected in the shares and shares are close to fair value.
07/06/17
07/06/17
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Schlumberger (SLB) upgraded to Outperform from Market Perform at Bernstein with analyst Colin Davies citing valuation. 2. Shire (SHPG) upgraded to Hold from Reduce at HSBC with analyst Steve McGarry saying any hemophilia-related headline risk should be largely reflected in the shares and shares are close to fair value. 3. O'Reilly Automotive (ORLY) upgraded to Neutral following sell-off at Goldman Sachs with analyst Matthew Fassler citing the sell-off in shares and saying he expects an improvement in trends in 2018. 4. Buffalo Wild Wings (BWLD) upgraded to Neutral from Underperform at Longbow. 5. ImmunoGen (IMGN) upgraded to Outperform from Sector Perform at RBC Capital. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
07/14/17
CANT
07/14/17
NO CHANGE
CANT
Worries about Shire hemophilia franchise overdone, says Cantor
After speaking with a pediatric hematology/oncology physician, Cantor analyst Louise Chen reports that the doctor said that uptake of Roche's (RHHBY) hemophilia treatment, ACE910, "will be gradual" because of safety concerns. The analyst says that worries about Shire's (SHPG_) hemophilia franchise are overdone. She keeps a $222 price target and an Overweight rating on the stock.
RHHBY Roche
$31.85

-0.09 (-0.28%)

07/06/17
UBSW
07/06/17
DOWNGRADE
UBSW
Neutral
Roche downgraded to Neutral from Buy at UBS
UBS analyst Jack Scannell downgraded Roche to Neutral saying he's become more cautious on oncology in general and that the shares are close to his fair value estimate. The analyst has a CHF 260 price target for the shares.

TODAY'S FREE FLY STORIES

CTL

CenturyLink

$23.37

0.15 (0.65%)

12:35
07/22/17
07/22
12:35
07/22/17
12:35
Periodicals
CenturyLink CEO disagrees with Minnesota Attorney General claims, Reuters says »

CenturyLink CEO Glen Post…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Aug

  • 08

    Aug

DB

Deutsche Bank

$18.22

-0.24 (-1.30%)

, JPM

JPMorgan

$90.89

-0.31 (-0.34%)

12:30
07/22/17
07/22
12:30
07/22/17
12:30
Periodicals
Deutsche Bank, JPMorgan to pay $148M to end yen Libor litigation, Reuters says »

Deutsche Bank (DB) and…

DB

Deutsche Bank

$18.22

-0.24 (-1.30%)

JPM

JPMorgan

$90.89

-0.31 (-0.34%)

C

Citi

$66.00

-0.36 (-0.54%)

HSBC

HSBC

$47.86

-0.25 (-0.52%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jul

  • 26

    Jul

  • 27

    Jul

  • 12

    Oct

  • 13

    Apr

  • 14

    Jul

  • 12

    Oct

VLKAY

Volkswagen

$32.98

-0.725 (-2.15%)

, BMWYY

BMW

$31.52

-0.73 (-2.26%)

12:20
07/22/17
07/22
12:20
07/22/17
12:20
Periodicals
EU regulators investigating German car cartel allegations, Reuters reports »

EU antitrust regulators…

VLKAY

Volkswagen

$32.98

-0.725 (-2.15%)

BMWYY

BMW

$31.52

-0.73 (-2.26%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VLKAY

Volkswagen

$32.98

-0.725 (-2.15%)

12:11
07/22/17
07/22
12:11
07/22/17
12:11
Periodicals
Seat chief sees CNG as an alternative to diesel, Reuters reports »

Seat, a wholly owned…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TM

Toyota

$109.31

-0.53 (-0.48%)

12:03
07/22/17
07/22
12:03
07/22/17
12:03
Periodicals
Toyota to begin mass EV production in China as early as 2019, Reuters says »

Toyota Motor is likely to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BA

Boeing

$212.14

1.86 (0.88%)

, EADSY

Airbus

$20.89

-0.08 (-0.38%)

11:57
07/22/17
07/22
11:57
07/22/17
11:57
Periodicals
Boeing looking to rely on more factory automation, WSJ reports »

Boeing (BA) is cutting…

BA

Boeing

$212.14

1.86 (0.88%)

EADSY

Airbus

$20.89

-0.08 (-0.38%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jul

PUGOY

Peugeot

$21.51

-0.716 (-3.22%)

, GM

General Motors

$36.07

-0.34 (-0.93%)

11:50
07/22/17
07/22
11:50
07/22/17
11:50
Periodicals
Open defends employee leases inclusion in sales figures, Reuters reports »

Opel, which is being…

PUGOY

Peugeot

$21.51

-0.716 (-3.22%)

GM

General Motors

$36.07

-0.34 (-0.93%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jul

FB

Facebook

$164.43

-0.1 (-0.06%)

, AAPL

Apple

$150.27

-0.07 (-0.05%)

11:39
07/22/17
07/22
11:39
07/22/17
11:39
Periodicals
Facebook, Apple troubles in China no longer a surprise, NY Times says »

Facebook (FB), Apple…

FB

Facebook

$164.43

-0.1 (-0.06%)

AAPL

Apple

$150.27

-0.07 (-0.05%)

MSFT

Microsoft

$73.79

-0.43 (-0.58%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jul

  • 01

    Aug

  • 05

    Sep

  • 13

    Sep

WFC

Wells Fargo

$54.17

-0.71 (-1.29%)

10:14
07/22/17
07/22
10:14
07/22/17
10:14
Periodicals
Wells Fargo investigating information sent to attorney, Bloomberg reports »

Wells Fargo said it is…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Oct

  • 15

    Jan

COKE

Coca-Cola Bottling

$240.86

-0.94 (-0.39%)

09:51
07/22/17
07/22
09:51
07/22/17
09:51
Hot Stocks
Coca-Cola Bottling announces 25c dividend for third quarter »

Coca-Cola Bottling…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PG

Procter & Gamble

$88.61

0.01 (0.01%)

09:41
07/22/17
07/22
09:41
07/22/17
09:41
Periodicals
Procter & Gamble finds itself 'besieged again,' Barron's says »

In a follow-up story,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Aug

PG

Procter & Gamble

$88.61

0.01 (0.01%)

09:40
07/22/17
07/22
09:40
07/22/17
09:40
Periodicals
Procter & Gamble finds itself 'besieged again,' Barron's says »

In a follow-up story,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Aug

DF

Dean Foods

$15.35

-0.02 (-0.13%)

09:33
07/22/17
07/22
09:33
07/22/17
09:33
Periodicals
Cheddar prices could rise further, Barron's says »

Prices for block cheddar…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Aug

KR

Kroger

, FDX

FedEx

$212.51

0.63 (0.30%)

09:25
07/22/17
07/22
09:25
07/22/17
09:25
Periodicals
Issuing debt to fund pensions 'not cause for worry,' Barron's says »

Issuing debt to fund…

KR

Kroger

FDX

FedEx

$212.51

0.63 (0.30%)

DAL

Delta Air Lines

$52.26

-0.57 (-1.08%)

DD

DuPont

$84.54

-0.29 (-0.34%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jul

SRPT

Sarepta

$43.41

2.48 (6.06%)

09:14
07/22/17
07/22
09:14
07/22/17
09:14
Periodicals
Upbeat sales news, guidance boost lift Sarepta shares, Barron's reports »

Sarepta's shares…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMZN

Amazon.com

$1,025.67

-3.03 (-0.29%)

, SHLD

Sears

$8.83

-0.77 (-8.02%)

09:09
07/22/17
07/22
09:09
07/22/17
09:09
Periodicals
Nothing is 'Amazon-proof,' Barron's says »

Amazon's (AMZN) deal…

AMZN

Amazon.com

$1,025.67

-3.03 (-0.29%)

SHLD

Sears

$8.83

-0.77 (-8.02%)

HD

Home Depot

$146.65

-0.38 (-0.26%)

LOW

Lowe's

$73.84

1.28 (1.76%)

BBY

Best Buy

$54.14

0.18 (0.33%)

M

Macy's

$23.36

0.29 (1.26%)

KSS

Kohl's

$40.46

0.47 (1.18%)

ORLY

O'Reilly Automotive

$188.19

-0.5 (-0.26%)

AAP

Advance Auto Parts

$105.27

2.04 (1.98%)

WFM

Whole Foods

$41.71

-0.05 (-0.12%)

KR

Kroger

COST

Costco

$150.44

-0.55 (-0.36%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Jul

  • 27

    Jul

  • 15

    Aug

  • 23

    Aug

  • 29

    Aug

BA

Boeing

$212.14

1.86 (0.88%)

, LMT

Lockheed Martin

$289.12

-0.55 (-0.19%)

08:58
07/22/17
07/22
08:58
07/22/17
08:58
Periodicals
Aviation, defense stocks have 'juicy yields,' Barron's says »

Some aerospace and…

BA

Boeing

$212.14

1.86 (0.88%)

LMT

Lockheed Martin

$289.12

-0.55 (-0.19%)

UTX

United Technologies

$123.49

1.04 (0.85%)

RTN

Raytheon

$169.37

0.59 (0.35%)

LLL

L3 Technologies

$176.62

-1.1 (-0.62%)

GD

General Dynamics

$204.55

2.15 (1.06%)

NOC

Northrop Grumman

$265.30

0.53 (0.20%)

COL

Rockwell Collins

$109.31

-0.04 (-0.04%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jul

  • 26

    Jul

  • 26

    Jul

  • 26

    Jul

  • 27

    Jul

  • 27

    Jul

  • 28

    Jul

  • 15

    Aug

  • 23

    Aug

AMZN

Amazon.com

$1,025.67

-3.03 (-0.29%)

, GOOGL

Alphabet Class A

$993.84

1.65 (0.17%)

08:50
07/22/17
07/22
08:50
07/22/17
08:50
Periodicals
Amazon, others could be threat to fiberoptic markers, Barron's says »

Amazon.com (AMZN),…

AMZN

Amazon.com

$1,025.67

-3.03 (-0.29%)

GOOGL

Alphabet Class A

$993.84

1.65 (0.17%)

GOOG

Alphabet

$972.92

4.77 (0.49%)

AAPL

Apple

$150.27

-0.07 (-0.05%)

FB

Facebook

$164.43

-0.1 (-0.06%)

AAOI

Applied Optoelectronics

$89.95

1.15 (1.30%)

LITE

Lumentum

$63.35

2.9 (4.80%)

OCLR

Oclaro

$9.90

0.04 (0.41%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jul

  • 26

    Jul

  • 27

    Jul

  • 01

    Aug

  • 02

    Aug

  • 03

    Aug

  • 05

    Sep

  • 13

    Sep

  • 13

    Sep

NKE

Nike

$59.95

0.85 (1.44%)

, FB

Facebook

$164.43

-0.1 (-0.06%)

08:28
07/22/17
07/22
08:28
07/22/17
08:28
Periodicals
AllianceBernstein's Caruso sees EPS as 'poor' report card, Barron's says »

Frank Caruso, the chief…

NKE

Nike

$59.95

0.85 (1.44%)

FB

Facebook

$164.43

-0.1 (-0.06%)

ISRG

Intuitive Surgical

$927.47

-44.26 (-4.55%)

ANET

Arista Networks

$152.92

-3.88 (-2.47%)

AB

AllianceBernstein

$24.75

0.1 (0.41%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jul

  • 27

    Jul

  • 27

    Jul

  • 03

    Aug

  • 08

    Aug

  • 16

    Aug

  • 17

    Aug

  • 21

    Aug

  • 13

    Sep

FLEX

Flex

$16.74

-0.07 (-0.42%)

, AAPL

Apple

$150.27

-0.07 (-0.05%)

07:53
07/22/17
07/22
07:53
07/22/17
07:53
Periodicals
Flex could rise 25% in a year, Barron's says »

Flex (FLEX) is using…

FLEX

Flex

$16.74

-0.07 (-0.42%)

AAPL

Apple

$150.27

-0.07 (-0.05%)

LNVGY

Lenovo

$12.63

0.18 (1.45%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Jul

  • 01

    Aug

LUK

Leucadia

$26.45

0.03 (0.11%)

07:46
07/22/17
07/22
07:46
07/22/17
07:46
Periodicals
Leucadia shareholders to 'finally' see reward, Barron's says »

Five years after Leucadia…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MS

Morgan Stanley

$46.59

0.08 (0.17%)

07:39
07/22/17
07/22
07:39
07/22/17
07:39
Periodicals
Morgan Stanley CEO would not kill off Dodd-Frank, Barron's reports »

Morgan Stanley CEO James…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MS

Morgan Stanley

$46.59

0.08 (0.17%)

, JPM

JPMorgan

$90.89

-0.31 (-0.34%)

07:34
07/22/17
07/22
07:34
07/22/17
07:34
Periodicals
Big bank profits could be lifted 30% by deregulation, Barron's says »

While a major overhaul is…

MS

Morgan Stanley

$46.59

0.08 (0.17%)

JPM

JPMorgan

$90.89

-0.31 (-0.34%)

GS

Goldman Sachs

$220.18

-2.12 (-0.95%)

C

Citi

$66.00

-0.36 (-0.54%)

STT

State Street

$90.99

0.12 (0.13%)

BK

BNY Mellon

$53.36

-0.55 (-1.02%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jul

  • 26

    Jul

  • 26

    Jul

  • 27

    Jul

  • 01

    Aug

  • 01

    Aug

  • 12

    Oct

  • 17

    Oct

  • 13

    Apr

  • 14

    Jul

  • 12

    Oct

BCC

Boise Cascade

$29.35

0.4 (1.38%)

, CAT

Caterpillar

$106.59

-0.73 (-0.68%)

07:19
07/22/17
07/22
07:19
07/22/17
07:19
Hot Stocks
Week in review: How Trump's policies moved stocks »

Catch up on the top…

BCC

Boise Cascade

$29.35

0.4 (1.38%)

CAT

Caterpillar

$106.59

-0.73 (-0.68%)

CPB

Campbell Soup

$52.00

0.08 (0.15%)

LVB

Steinway Musical

GLW

Corning

$31.85

0.14 (0.44%)

MRK

Merck

$62.63

-0.31 (-0.49%)

PFE

Pfizer

$33.48

-0.06 (-0.18%)

AMZN

Amazon.com

$1,025.67

-3.03 (-0.29%)

AET

Aetna

$156.31

0.58 (0.37%)

ANTM

Anthem

$190.65

-0.04 (-0.02%)

CNC

Centene

$84.73

-0.67 (-0.78%)

CI

Cigna

$174.23

-0.26 (-0.15%)

HNT

Health Net

HUM

Humana

$235.92

0.09 (0.04%)

MOH

Molina Healthcare

$71.15

-0.9 (-1.25%)

UNH

UnitedHealth

$191.78

0.28 (0.15%)

WCG

WellCare

$183.87

0.1 (0.05%)

X

U.S. Steel

$23.68

-0.47 (-1.95%)

STLD

Steel Dynamics

$37.51

-0.18 (-0.48%)

NUE

Nucor

$60.23

0.31 (0.52%)

CYH

Community Health

$9.27

0.01 (0.11%)

HCA

HCA Holdings

$85.73

-0.03 (-0.03%)

LPNT

LifePoint

$65.35

-0.15 (-0.23%)

THC

Tenet

$20.65

-0.02 (-0.10%)

UHS

Universal Health

$124.42

-0.58 (-0.46%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jul

  • 25

    Jul

  • 25

    Jul

  • 26

    Jul

  • 26

    Jul

  • 26

    Jul

  • 26

    Jul

  • 27

    Jul

  • 27

    Jul

  • 28

    Jul

  • 30

    Jul

  • 01

    Aug

  • 01

    Aug

  • 02

    Aug

  • 02

    Aug

  • 02

    Aug

  • 02

    Aug

  • 03

    Aug

  • 03

    Aug

  • 04

    Aug

  • 04

    Aug

  • 08

    Aug

  • 14

    Aug

  • 23

    Aug

  • 27

    Aug

  • 22

    Sep

  • 26

    Sep

  • 27

    Sep

MET

MetLife

$54.65

0.07 (0.13%)

18:20
07/21/17
07/21
18:20
07/21/17
18:20
Periodicals
U.S. regulators to go over MetLife suit at July 28 meeting, Reuters says »

Leaders at the U.S.…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Aug

  • 14

    Aug

  • 15

    Aug

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.